# Vir hepatitis D drug succeeds in first pivotal study

Source: [BioPharma Dive - Latest News](https://www.biopharmadive.com/news/vir-chronic-hepatitis-d-drug-results-elebsiran-tobevibart/874089/) · 2026-11-09 · Medicine
Page: https://themorning.science/story/vir-hepatitis-d-drug-succeeds-in-first-pivotal-study-ad29625b72e34a28
Kind: research · Impact: medium

## In brief

- Vir Biotechnology's hepatitis D drug hit all study objectives in its first pivotal study.
- The program survived Vir's pivot away from infectious disease research.
- The drug appeared more potent than a rival hepatitis D drug also in late-stage development.

## Why it matters

Hepatitis D is a severe form of viral hepatitis with limited treatment options, so a positive pivotal result signals a possible new therapy for patients and is a step toward regulatory review.

## Timeline

- 2026-11-09: BioPharma Dive reports that Vir's hepatitis D drug succeeded in its first pivotal study

## Coverage

- [Vir hepatitis D drug succeeds in first pivotal study](https://www.biopharmadive.com/news/vir-chronic-hepatitis-d-drug-results-elebsiran-tobevibart/874089/) — BioPharma Dive - Latest News, 2026-11-09

Tags: hepatitis d, vir biotechnology, clinical trial, antiviral, drug development

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science